Skip to main content
Journal of Epidemiology logoLink to Journal of Epidemiology
. 2021 Dec 5;31(12):660–668. doi: 10.2188/jea.JE20200147

Study Profile of the Japan Multi-institutional Collaborative Cohort (J-MICC) Study

Kenji Takeuchi 1,*, Mariko Naito 1,2,*, Sayo Kawai 1,3, Mineko Tsukamoto 1, Yuka Kadomatsu 1, Yoko Kubo 1, Rieko Okada 1, Mako Nagayoshi 1, Takashi Tamura 1, Asahi Hishida 1, Masahiro Nakatochi 4, Tae Sasakabe 1,3, Shuji Hashimoto 5, Hidetaka Eguchi 6, Yukihide Momozawa 7, Hiroaki Ikezaki 8,9, Masayuki Murata 9, Norihiro Furusyo 10, Keitaro Tanaka 11, Megumi Hara 11, Yuichiro Nishida 11, Keitaro Matsuo 12,13, Hidemi Ito 14,15, Isao Oze 12, Haruo Mikami 16, Yohko Nakamura 16, Miho Kusakabe 16, Toshiro Takezaki 17, Rie Ibusuki 17, Ippei Shimoshikiryo 17, Sadao Suzuki 18, Takeshi Nishiyama 18, Miki Watanabe 18, Teruhide Koyama 19, Etsuko Ozaki 19, Isao Watanabe 19, Kiyonori Kuriki 20, Yoshikuni Kita 21, Hirotsugu Ueshima 22, Kenji Matsui 23, Kokichi Arisawa 24, Hirokazu Uemura 24,25, Sakurako Katsuura-Kamano 24, Sho Nakamura 26,27, Hiroto Narimatsu 26,27, Nobuyuki Hamajima 28, Hideo Tanaka 29, Kenji Wakai 1, for the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study
PMCID: PMC8593573  PMID: 32963210

Abstract

Background

The Japan Multi-institutional Collaborative Cohort (J-MICC) study was launched in 2005 to examine gene–environment interactions in lifestyle-related diseases, including cancers, among the Japanese. This report describes the study design and baseline profile of the study participants.

Methods

The participants of the J-MICC Study were individuals aged 35 to 69 years enrolled from respondents to study announcements in specified regions, inhabitants attending health checkup examinations provided by local governments, visitors at health checkup centers, and first-visit patients at a cancer hospital in Japan. At the time of the baseline survey, from 2005 to 2014, we obtained comprehensive information regarding demographics, education, alcohol consumption, smoking, sleeping, exercise, food intake frequency, medication and supplement use, personal and family disease history, psychological stress, and female reproductive history and collected peripheral blood samples.

Results

The baseline survey included 92,610 adults (mean age: 55.2 [standard deviation, 9.4] years, 44.1% men) from 14 study regions in 12 prefectures. The participation rate was 33.5%, with participation ranging from 19.7% to 69.8% in different study regions. The largest number of participants was in the age groups of 65–69 years for men and 60–64 years for women. There were differences in body mass index, educational attainment, alcohol consumption, smoking, and sleep duration between men and women.

Conclusions

The J-MICC Study collected lifestyle and clinical data and biospecimens from over 90,000 participants. This cohort is expected to be a valuable resource for the national and international scientific community in providing evidence to support longer healthy lives.

Key words: study profile, cohort study, gene–environment interactions, cancer, J-MICC

INTRODUCTION

Since 1981, cancer, a lifestyle-related disease, has been the leading cause of death in Japan and has continued to be a substantial public health burden. In Japan, several cohort studies were started in the 1980s and 1990s to identify factors contributing to the decrease in the incidence of lifestyle-related diseases represented by cancer. Representative large-scale cohort studies for cancer prevention include the following. From 1988 through 1990, the Japan Collaborative Cohort (JACC) study was established, covering 45 regions in Japan, and has followed up approximately 110,000 individuals aged 40 to 79 years.1 From 1990 to 1993, the Japan Public Health Center-based Cohort (JPHC) study began covering 11 public health center regions throughout Japan and has included a total of about 140,000 individuals aged 40 to 69 years.2 However, cancer is still the leading cause of death, resulting in approximately 0.37 million deaths (27.4% of all deaths) in 2018.3

With recent advances in genotyping techniques, gene–environment interactions in lifestyle-related diseases have begun to be investigated in many epidemiological studies.48 This is because most multifactorial diseases are considered to be caused by interactions between hazardous environmental factors and the host genome. Elucidating gene–environment interactions requires long-term cohort studies, which cover the etiologically relevant time period to improve the accuracy of measures of exposures by collecting repeated biologic samples and self-reported information.9 Therefore, we launched the Japan Multi-institutional Collaborative Cohort (J-MICC) study in 2005, which includes healthy Japanese individuals. As part of this study, buffy coat, serum, and plasma samples are stored. The J-MICC Study is supported by a research grant for Scientific Research on Special Priority Areas of Cancer from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT).10 The aims of this large-scale, population-based, long-term prospective, genome-cohort study are to examine gene–environment interactions in lifestyle-related diseases, especially cancers. While the J-MICC Study Group reported many cross-sectional studies focusing on the gene–environmental interaction for health outcomes, there were no reports of detailed study design and baseline participant age distribution by study region. Therefore, this report describes the study design and profile of the participants at baseline.

METHODS

Study design and organization

The J-MICC Study is being conducted under a population-based cohort design, managed by 13 research groups (J-MICC Study Group) from 12 prefectures: Chiba Cancer Center Research Institute, Kanagawa Cancer Center Research Institute, University of Shizuoka, Nagoya City University, Aichi Cancer Center Research Institute, Nagoya University, Tsuruga Nursing University, Shiga University of Medical Science, Kyoto Prefectural University of Medicine, Tokushima University Graduate School, Kyushu University, Saga University, and Kagoshima University. Each group has its own independent research site and conducts a cohort study as part of the J-MICC Study, which allows sites to collect and analyze additional information or samples for their own research purposes. The Steering Committee is organized by a representative from each group to manage and control the progress of the whole J-MICC Study. The chief investigator of the J-MICC Study is the chairperson of the Steering Committee. The central office was established at Nagoya University Graduate School of Medicine, where all J-MICC data and half of all blood samples are preserved. The central office also makes efforts to standardize the processes in each cohort study, supplies common tools (eg, data input system, sample management system, posters, brochures), and maintains the study website (http://www.jmicc.com/). The study protocol of the J-MICC Study was approved by the ethics committee of Nagoya University Graduate School of Medicine (approval number: 253), as well as by each group in the research sites. All participants provided written informed consent after a thorough explanation of the outline and objectives of this study.

Study participants

The participants of the J-MICC Study were individuals aged 35 through 69 years living in Japan. At the time of the baseline survey, from 2005–2014, the participants completed questionnaires and provided peripheral blood samples. The baseline study participants were recruited from 14 different regions throughout Japan (Figure 1). The study regions included Chiba, Shizuoka-Sakuragaoka, Shizuoka, Okazaki, Aichi Cancer Center, Daiko, Iga, Takashima, Kyoto, Tokushima, Fukuoka, Saga, Kagoshima, and the Kyusyu and Okinawa Population Study (KOPS) area. The subject sources are inhabitants in communities in four regions (Chiba, Daiko, Fukuoka, and Saga), health checkup examinees in seven regions (Shizuoka-Sakuragaoka, Shizuoka, Okazaki, Iga, Takashima, Kagoshima, and KOPS), and first-visit patients at a cancer hospital in Aichi Cancer Center region. In Kyoto and Tokushima regions, the subject sources are inhabitants in communities and health checkup examinees as well as employees of companies or local governments. In six regions (Shizuoka-Sakuragaoka, Okazaki, Takashima, Kyoto, Fukuoka, and KOPS), individuals under 35 and/or over 70 years of age were also recruited as study participants. In the Fukuoka and Saga regions, individuals aged 50 years or older and 40 years or older in principle were recruited, respectively. In the Fukuoka and KOPS regions, the survey started earlier (in 2004) and Kyushu University has been operating in study regions and collaborating with groups in the J-MICC Study. In the Kanagawa region, the baseline survey started in 2016 and is still ongoing.

Figure 1. Locations of the study regions of the J-MICC Study. *Baseline survey started in 2016 and ongoing. aInhabitants in communities; bHealth checkup examinees; cEmployees of companies or local governments; dFirst-visit patients at a cancer hospital.

Figure 1.

Follow-up survey

The secondary survey, which is the same as the baseline survey, is scheduled for approximately 5 years after baseline enrollment, and participants will be followed until 2025. The endpoints of the J-MICC Study are cancer incidence and death from any cause, while incidence of cerebrovascular disease and myocardial infarction has been additionally registered in 10 study regions. As stated,10 information regarding endpoints are collected through population-based cancer registries if available, lists of patients at main hospitals in the study regions, mail questionnaires sent to participants, questionnaires at repeated visits to health checkup facilities, notes from death certificates, information from health insurance data, and secondary survey questionnaires. The incidence data other than those from cancer registries are also confirmed using hospital records. When a participant moves out of the study region, the participant’s follow-up is censored.

Longitudinal analyses of the follow-up survey data will be conducted in the near future.

Data and blood samples collection

At the time of enrollment, the self-administered questionnaire was distributed to the entire target population, which included common questions across all study regions. Table 1 summarizes the common questions covering basic, lifestyle, and clinical characteristics. In addition, blood chemistry data and anthropometric data were obtained from health check-ups at enrollment. The data collected from health check-ups to be sent to the central office were previously reported.10

Table 1. Summary of common questions in the self-administered questionnaire for all study regions at baseline.

Measurements Measurement lists
Basic characteristics  
 Demographics Sex, age at baseline, height, weight, and weight at the age of 20 years
 Education* Educational attainment
Lifestyle characteristics  
 Alcohol consumption Drinking status, age when the individual started drinking, type and amount of alcohol consumed, and drinking frequency
 Smoking Smoking status, age when the individual started smoking, number of cigarettes smoked, and information on passive smoking
 Sleeping Sleeping duration and subjective assessment of sleep
 Exercise Physical activity (including leisure-time, occupational, and household activities)
 Diet Food intake frequency
Clinical characteristics  
 Medication and supplements Types of medications and supplements taken at least once a week
 Disease history Personal and family disease history
 Psychological stress Self-reported stress and stress management
 Female reproductive history Menstruation status, age at the start of menstruation, and information on pregnancy and childbirth

*Excluding 3 regions (Iga, Fukuoka, and Kyusyu and Okinawa Population Study regions).

We collected blood samples in a 7-mL vacuum tube for serum and a 7-mL EDTA-2Na-containing vacuum tube for plasma and buffy coat. The blood samples sent to the central office consisted of one tube containing 300 µL of buffy coat, four tubes containing 300 µL of serum, and four tubes containing 300 µL of plasma. Some of the blood specimens will be stored at the central office until the end of the J-MICC Study in 2035.11

Baseline data and blood samples (buffy coat, serum, and plasma), anonymized with an identification number (J-MICC ID), are sent to the central office from each participating research group. The secondary survey and follow-up data are linked using the J-MICC ID.

Statistical analyses

For the baseline profile (excluding the Kanagawa region because of the ongoing baseline survey for 5,000 participants), descriptive statistics were calculated for baseline data regarding sex, age, body mass index (BMI) calculated from self-reported height and weight, educational attainment, alcohol consumption, smoking, sleeping duration, leisure time physical activity, psychological stress, and personal (past and present) disease history. In the case of educational attainment, participants from the Iga, Fukuoka, and KOPS regions were excluded from the analysis because the questionnaire used there did not include this item.

RESULTS

Among 247,951 eligible individuals, 83,114 (33.5% in total with response rates ranging from 19.7% to 69.8% in different study regions) consented to participate in the baseline survey of the J-MICC Study. Furthermore, by distributing 2,786,327 fliers via mailboxes in four regions, 18,368 respondents were additionally recruited. In total, 101,482 men and women participated in the baseline survey. After excluding 8,294 respondents under 35 or over 70 years of age and 578 who withdrew consent or became ineligible, the remaining 92,610 participants (40,880 men and 51,730 women with an average age of 55.2 [standard deviation, 9.4] years) in the baseline survey were included in the present analysis (the dataset was fixed on February 2, 2020). Among the participants, 90,319 people (97.5% of total participants) consented to the use of their biospecimens in the J-MICC Study, including genomic analysis (90,252 people; 99.9% of total consenters).

The age-sex distribution of the participants in the baseline survey is presented in Figure 2. Of the respondents, 7.2% belonged to the 35–39 years age group, 9.7% to the 40–44 years age group, 11.1% to the 45–49 years age group, 14.4% to the 50–54 years age group, 18.0% to the 55–59 years age group, 20.5% to the 60–64 years age group, and 19.1% to the 65–69 years age group. The largest number of participants were in the 65–69 age group for men (21.7% of male participants) and the 60–64 age group for women (19.6% of female participants). The number of female participants was higher than that of male participants for all age categories, except for those aged 65–69.

Figure 2. Age-sex distribution of participants in the baseline survey of the J-MICC Study.

Figure 2.

The age distribution of the male and female participants in the baseline survey by the study regions is shown in Table 2 and Table 3, respectively. The average age of participants who were enrolled in Chiba, Shizuoka-Sakuragaoka, Shizuoka, Okazaki, Aichi Cancer Center, Daiko, Iga, Takashima, Kyoto, Tokushima, Fukuoka, Saga, Kagoshima, and KOPS regions were 53.9, 54.8, 52.2, 55.8, 55.1, 52.5, 51.2, 57.7, 51.6, 50.6, 60.3, 56.0, 57.5, and 54.7 years, respectively. There were considerable differences in age distributions by study region among both men and women. Notably, the percentage of people aged 35 to 39 years ranged from 0.0% to 16.7% in men and from 0.0% to 16.0% in women. Likewise, the percentage of people aged 40 to 44 years and 45 to 49 years ranged from 0.0% to 16.1% and 0.0% to 15.9% in men and from 0.0% to 16.5% and 0.1% to 18.1% in women, respectively.

Table 2. Age distribution of male participants in the baseline survey of the J-MICC Study by study region.

Study region   Age, years Total Average age
(SD)

  35–39 40–44 45–49 50–54 55–59 60–64 65–69
Total N 2,608 3,549 4,026 5,720 7,232 8,854 8,891 40,880 56.1
  (%) (6.4) (8.7) (9.8) (14.0) (17.7) (21.7) (21.7) (100.0) (9.3)
Chiba N 293 272 292 347 455 562 697 2,918 55.4
  (%) (10.0) (9.3) (10.0) (11.9) (15.6) (19.3) (23.9) (100.0) (10.1)
Shizuoka-Sakuragaoka N 240 277 286 435 521 808 563 3,130 55.6
  (%) (7.7) (8.8) (9.1) (13.9) (16.6) (25.8) (18.0) (100.0) (9.3)
Shizuoka N 265 437 542 585 782 483 312 3,406 52.7
  (%) (7.8) (12.8) (15.9) (17.2) (23.0) (14.2) (9.2) (100.0) (8.7)
Okazaki N 262 271 353 376 449 824 955 3,490 56.7
  (%) (7.5) (7.8) (10.1) (10.8) (12.9) (23.6) (27.4) (100.0) (9.7)
Aichi Cancer Center N 192 225 301 462 837 1,119 1,159 4,295 58.2
  (%) (4.5) (5.2) (7.0) (10.8) (19.5) (26.1) (27.0) (100.0) (8.6)
Daiko N 190 161 185 195 206 241 284 1,462 53.6
  (%) (13.0) (11.0) (12.7) (13.3) (14.1) (16.5) (19.4) (100.0) (10.3)
Iga N 100 94 76 115 89 94 68 636 51.3
  (%) (15.7) (14.8) (11.9) (18.1) (14.0) (14.8) (10.7) (100.0) (9.8)
Takashima N 72 58 78 87 161 305 477 1,238 59.3
  (%) (5.8) (4.7) (6.3) (7.0) (13.0) (24.6) (38.5) (100.0) (9.1)
Kyoto N 431 344 360 369 346 385 341 2,576 51.7
  (%) (16.7) (13.4) (14.0) (14.3) (13.4) (14.9) (13.2) (100.0) (10.3)
Tokushima N 224 228 191 225 218 221 107 1,414 50.8
  (%) (15.8) (16.1) (13.5) (15.9) (15.4) (15.6) (7.6) (100.0) (9.6)
Fukuoka N 0 0 0 782 1,131 1,256 1,287 4,456 60.5
  (%) (0.0) (0.0) (0.0) (17.5) (25.4) (28.2) (28.9) (100.0) (5.4)
Saga N 0 569 591 793 1,048 1,025 1,052 5,078 56.5
  (%) (0.0) (11.2) (11.6) (15.6) (20.6) (20.2) (20.7) (100.0) (8.2)
Kagoshima N 79 230 366 435 465 738 847 3,160 57.5
  (%) (2.5) (7.3) (11.6) (13.8) (14.7) (23.4) (26.8) (100.0) (8.6)
KOPS N 260 383 405 514 524 793 742 3,621 55.3
  (%) (7.2) (10.6) (11.2) (14.2) (14.5) (21.9) (20.5) (100.0) (9.6)

KOPS, Kyusyu and Okinawa Population Study; SD, standard deviation.

Table 3. Age distribution of female participants in the baseline survey of the J-MICC Study by study region.

Study region   Age, years Total Average age
(SD)

  35–39 40–44 45–49 50–54 55–59 60–64 65–69
Total N 4,078 5,427 6,283 7,621 9,406 10,153 8,762 51,730 54.6
  (%) (7.9) (10.5) (12.1) (14.7) (18.2) (19.6) (16.9) (100.0) (9.4)
Chiba N 636 607 703 732 854 894 750 5,176 53.1
  (%) (12.3) (11.7) (13.6) (14.1) (16.5) (17.3) (14.5) (100.0) (9.8)
Shizuoka-Sakuragaoka N 215 288 339 343 406 456 340 2,387 53.6
  (%) (9.0) (12.1) (14.2) (14.4) (17.0) (19.1) (14.2) (100.0) (9.5)
Shizuoka N 195 198 290 296 331 186 104 1,600 51.2
  (%) (12.2) (12.4) (18.1) (18.5) (20.7) (11.6) (6.5) (100.0) (8.6)
Okazaki N 220 331 411 411 506 657 524 3,060 54.7
  (%) (7.2) (10.8) (13.4) (13.4) (16.5) (21.5) (17.1) (100.0) (9.4)
Aichi Cancer Center N 572 656 759 659 791 807 562 4,806 52.3
  (%) (11.9) (13.6) (15.8) (13.7) (16.5) (16.8) (11.7) (100.0) (9.6)
Daiko N 570 489 542 472 470 558 589 3,690 52.1
  (%) (15.4) (13.3) (14.7) (12.8) (12.7) (15.1) (16.0) (100.0) (10.3)
Iga N 97 121 127 149 137 104 51 786 51.0
  (%) (12.3) (15.4) (16.2) (19.0) (17.4) (13.2) (6.5) (100.0) (8.7)
Takashima N 221 139 175 232 347 575 601 2,290 56.8
  (%) (9.7) (6.1) (7.6) (10.1) (15.2) (25.1) (26.2) (100.0) (9.8)
Kyoto N 544 552 588 488 444 576 428 3,620 51.5
  (%) (15.0) (15.2) (16.2) (13.5) (12.3) (15.9) (11.8) (100.0) (10.0)
Tokushima N 164 169 161 166 148 136 82 1,026 50.4
  (%) (16.0) (16.5) (15.7) (16.2) (14.4) (13.3) (8.0) (100.0) (9.5)
Fukuoka N 0 0 3 1,051 1,617 1,538 1,428 5,637 60.0
  (%) (0.0) (0.0) (0.1) (18.6) (28.7) (27.3) (25.3) (100.0) (5.3)
Saga N 0 921 940 1,150 1,409 1,374 1,196 6,990 55.6
  (%) (0.0) (13.2) (13.4) (16.5) (20.2) (19.7) (17.1) (100.0) (8.2)
Kagoshima N 60 313 497 617 850 1,074 1,067 4,478 57.5
  (%) (1.3) (7.0) (11.1) (13.8) (19.0) (24.0) (23.8) (100.0) (8.1)
KOPS N 584 643 748 855 1,096 1,218 1,040 6,184 54.3
  (%) (9.4) (10.4) (12.1) (13.8) (17.7) (19.7) (16.8) (100.0) (9.7)

KOPS, Kyusyu and Okinawa Population Study; SD, standard deviation.

Basic, lifestyle, and clinical characteristics of the male and female participants in the baseline survey by age category are summarized in Table 4 and Table 5, respectively. There were differences in BMI, educational attainment, alcohol consumption, smoking, and sleep duration between men and women. The percentage of overweight adults (BMI 25.0–29.9 kg/m2) was 1.7 times higher for men (26.7%) than for women (15.8%). Approximately 40% of men had ≥16 years of education compared with 13.5% of women. The likelihood of being a former drinker and sleeping ≥9 hours/day increased gradually with higher age categories among men, but no such association was observed among women. The likelihood of being a never smoker increased gradually with higher age categories among women, but no such association was observed among men. For leisure time physical activity, psychological stress, and history of disease, the percentages of participants with ≥300 min/week of leisure-time activity, those perceiving no stress, and those with a history of diseases increased gradually with higher age categories among both men and women. For cancer, when patients first seen at the Aichi Cancer Center, a cancer hospital, were excluded from the analysis, cancer prevalence fell from 8.5% to 4.5% for men and from 7.1% to 5.1% for women.

Table 4. Baseline characteristics of male participants of the J-MICC Study according to age category (N = 40,880).

Characteristic Age, years Total

35–39 40–44 45–49 50–54 55–59 60–64 65–69

N % N % N % N % N % N % N % N %
Body mass index, kg/m2                                
 <18.5 87 3.3 99 2.8 105 2.6 136 2.4 207 2.9 281 3.2 298 3.4 1,213 3.0
 18.5–24.9 1,742 66.8 2,288 64.5 2,553 63.4 3,618 63.3 4,840 66.9 6,080 68.7 6,291 70.8 27,412 67.1
 25.0–29.9 640 24.6 952 26.9 1,198 29.8 1,730 30.3 1,989 27.5 2,278 25.7 2,141 24.1 10,928 26.7
 ≥30.0 137 5.3 206 5.8 169 4.2 234 4.1 194 2.7 209 2.4 152 1.7 1,301 3.2
Educational attainment, years                            
 <10 45 2.0 94 3.1 100 2.8 197 4.6 460 8.4 944 14.2 1,482 22.0 3,322 10.4
 10–15 1,005 44.8 1,442 47.1 1,674 47.4 2,052 47.8 2,843 52.1 3,503 52.6 3,324 49.4 15,843 49.5
 ≥16 1,193 53.2 1,526 49.8 1,758 49.8 2,048 47.7 2,156 39.5 2,213 33.2 1,927 28.6 12,821 40.1
Alcohol consumption                                
 Current drinkers 1,902 72.9 2,679 75.5 3,163 78.6 4,465 78.2 5,500 76.1 6,646 75.1 6,507 73.3 30,862 75.6
 Former drinkers 36 1.4 74 2.1 87 2.2 177 3.1 281 3.9 423 4.8 552 6.2 1,630 4.0
 Never drinkers 670 25.7 794 22.4 775 19.3 1,070 18.7 1,443 20.0 1,781 20.1 1,821 20.5 8,354 20.5
Smoking                                
 Current smokers 879 34.0 1,310 37.1 1,416 35.3 2,052 36.0 2,364 32.7 2,368 26.8 1,772 20.0 12,161 29.8
 Former smokers 713 27.6 1,066 30.2 1,393 34.7 2,206 38.7 3,097 42.9 4,160 47.1 4,382 49.4 17,017 41.7
 Never smokers 990 38.3 1,159 32.8 1,200 29.9 1,444 25.3 1,763 24.4 2,305 26.1 2,722 30.7 11,583 28.4
Sleep duration, hour/day                                
 <4.0 10 0.4 12 0.3 9 0.2 8 0.1 12 0.2 11 0.1 18 0.2 80 0.2
 4.0–4.9 77 3.0 74 2.1 73 1.8 71 1.2 70 1.0 113 1.3 85 1.0 563 1.4
 5.0–5.9 364 14.0 452 12.7 469 11.7 639 11.2 618 8.6 555 6.3 560 6.3 3,657 9.0
 6.0–6.9 1,027 39.5 1,400 39.5 1,553 38.6 1,999 35.0 2,415 33.4 2,372 26.8 2,087 23.5 12,853 31.5
 7.0–7.9 801 30.8 1,133 32.0 1,374 34.2 2,105 36.8 2,710 37.5 3,249 36.7 3,117 35.1 14,489 35.5
 8.0–8.9 292 11.2 437 12.3 485 12.1 797 14.0 1,230 17.0 2,167 24.5 2,443 27.5 7,851 19.2
 ≥9.0 30 1.2 38 1.1 59 1.5 94 1.6 168 2.3 380 4.3 572 6.4 1,341 3.3
Leisure time physical activity, min/week                            
 <30 1,078 42.7 1,544 44.6 1,631 41.7 2,206 39.6 2,555 36.4 2,386 27.8 1,878 22.1 13,278 33.6
 30–59 231 9.2 302 8.7 303 7.7 405 7.3 487 6.9 452 5.3 305 3.6 2,485 6.3
 60–119 449 17.8 550 15.9 696 17.8 964 17.3 1,203 17.1 1,206 14.1 951 11.2 6,019 15.2
 120–179 255 10.1 361 10.4 406 10.4 626 11.2 828 11.8 937 10.9 906 10.7 4,319 10.9
 180–299 206 8.2 280 8.1 354 9.0 560 10.0 780 11.1 1,100 12.8 1,091 12.9 4,371 11.1
 ≥300 304 12.0 427 12.3 525 13.4 815 14.6 1,168 16.6 2,496 29.1 3,349 39.5 9,084 23.0
Psychological stress during the last year                            
 No stress 30 1.2 70 2.0 108 2.8 180 3.2 331 4.7 680 7.8 955 10.9 2,354 5.9
 Low stress 375 15.0 494 14.3 627 16.0 1,086 19.4 1,654 23.3 3,011 34.5 3,475 39.6 10,722 26.8
 Moderate stress 1,254 50.2 1,674 48.6 1,936 49.3 2,713 48.5 3,443 48.5 3,800 43.6 3,510 40.0 18,330 45.8
 High stress 838 33.6 1,207 35.0 1,253 31.9 1,612 28.8 1,676 23.6 1,226 14.1 840 9.6 8,652 21.6
Personal disease history                                
 Diabetes 28 1.1 106 3.0 185 4.6 352 6.6 744 11.1 1,162 14.0 1,194 14.4 3,771 9.7
 Hypertension 105 4.0 264 7.4 559 13.9 1,087 20.2 1,835 27.0 2,847 34.1 3,305 39.1 10,002 25.6
 Dyslipidemia 147 5.6 352 9.9 596 14.9 923 17.2 1,320 19.7 1,618 19.7 1,569 19.0 6,525 16.9
 Coronary heart disease 11 0.4 25 0.7 57 1.4 120 2.3 249 3.8 472 5.8 662 8.1 1,596 4.2
 Stroke 4 0.2 16 0.5 26 0.6 78 1.5 150 2.3 297 3.6 365 4.5 936 2.4
 Cancer 52 2.1 76 2.2 132 3.4 257 5.1 577 9.0 909 11.4 1,159 14.7 3,162 8.5

Table 5. Baseline characteristics of female participants of the J-MICC Study according to age category (N = 51,730).

Characteristic Age, years Total

35–39 40–44 45–49 50–54 55–59 60–64 65–69

N % N % N % N % N % N % N % N %
Body mass index, kg/m2                                
 <18.5 746 18.4 706 13.0 639 10.2 652 8.6 766 8.2 725 7.2 562 6.4 4,796 9.3
 18.5–24.9 2,900 71.4 3,935 72.6 4,582 73.0 5,581 73.3 6,772 72.1 7,377 72.8 6,154 70.4 37,301 72.2
 25.0–29.9 323 8.0 630 11.6 889 14.2 1,175 15.4 1,614 17.2 1,794 17.7 1,735 19.8 8,160 15.8
 ≥30.0 90 2.2 147 2.7 166 2.6 208 2.7 242 2.6 243 2.4 294 3.4 1,390 2.7
Educational attainment, years                            
 <10 58 1.7 60 1.3 91 1.7 190 3.4 542 8.3 1,052 14.5 1,523 24.6 3,516 9.0
 10–15 2,413 71.4 3,682 79.2 4,367 81.0 4,471 80.6 5,273 81.0 5,619 77.5 4,314 69.8 30,139 77.5
 ≥16 908 26.9 905 19.5 931 17.3 887 16.0 696 10.7 582 8.0 346 5.6 5,255 13.5
Alcohol consumption                                
 Current drinkers 1,959 48.1 2,607 48.1 2,896 46.2 3,077 40.4 3,219 34.3 3,137 31.0 2,276 26.0 19,171 37.1
 Former drinkers 158 3.9 124 2.3 101 1.6 150 2.0 173 1.8 176 1.7 157 1.8 1,039 2.0
 Never drinkers 1,956 48.0 2,690 49.6 3,275 52.2 4,386 57.6 5,999 63.9 6,817 67.3 6,320 72.2 31,443 60.9
Smoking                                
 Current smokers 442 10.9 557 10.3 649 10.4 697 9.2 653 7.0 474 4.7 252 2.9 3,724 7.2
 Former smokers 567 14.0 544 10.1 610 9.8 649 8.6 613 6.6 514 5.1 337 3.9 3,834 7.5
 Never smokers 3,042 75.1 4,292 79.6 4,975 79.8 6,230 82.2 8,089 86.5 9,124 90.2 8,145 93.3 43,897 85.3
Sleep duration, hour/day                                
 <4.0 7 0.2 17 0.3 21 0.3 22 0.3 15 0.2 28 0.3 33 0.4 143 0.3
 4.0–4.9 79 1.9 127 2.3 158 2.5 154 2.0 181 1.9 171 1.7 153 1.7 1,023 2.0
 5.0–5.9 474 11.6 853 15.7 1,093 17.4 1,226 16.1 1,211 12.9 1,022 10.1 958 10.9 6,837 13.2
 6.0–6.9 1,451 35.6 2,201 40.6 2,722 43.4 3,242 42.6 3,540 37.7 3,281 32.3 2,572 29.4 19,009 36.8
 7.0–7.9 1,348 33.1 1,624 30.0 1,776 28.3 2,293 30.1 3,302 35.2 3,886 38.3 3,241 37.0 17,470 33.8
 8.0–8.9 630 15.5 546 10.1 461 7.3 629 8.3 1,060 11.3 1,592 15.7 1,576 18.0 6,494 12.6
 ≥9.0 86 2.1 53 1.0 45 0.7 49 0.6 83 0.9 166 1.6 223 2.5 705 1.4
Leisure time physical activity, min/week                            
 <30 1,931 49.2 2,602 49.2 2,811 46.3 3,071 41.7 3,235 35.7 2,795 28.9 2,123 25.8 18,568 37.4
 30–59 346 8.8 442 8.4 465 7.7 510 6.9 574 6.3 486 5.0 408 5.0 3,231 6.5
 60–119 508 12.9 733 13.9 763 12.6 1,020 13.9 1,190 13.1 1,193 12.3 970 11.8 6,377 12.9
 120–179 384 9.8 566 10.7 692 11.4 856 11.6 1,150 12.7 1,312 13.6 1,059 12.9 6,019 12.1
 180–299 311 7.9 423 8.0 586 9.7 825 11.2 1,129 12.5 1,275 13.2 1,163 14.1 5,712 11.5
 ≥300 446 11.4 522 9.9 751 12.4 1,082 14.7 1,777 19.6 2,600 26.9 2,499 30.4 9,677 19.5
Psychological stress during the last year                            
 No stress 23 0.6 35 0.7 61 1.0 110 1.5 180 1.9 358 3.6 480 5.5 1,247 2.5
 Low stress 435 11.0 538 10.2 708 11.5 1,023 13.7 1,559 16.9 2,088 20.9 2,191 25.3 8,542 16.8
 Moderate stress 1,897 47.8 2,553 48.3 2,968 48.4 3,676 49.4 4,623 50.0 4,971 49.7 4,235 48.8 24,923 49.1
 High stress 1,615 40.7 2,163 40.9 2,398 39.1 2,632 35.4 2,879 31.2 2,578 25.8 1,764 20.3 16,029 31.6
Personal disease history                                
 Diabetes 18 0.4 39 0.7 73 1.2 156 2.2 375 4.3 538 5.7 555 6.9 1,754 3.6
 Hypertension 61 1.5 155 2.9 359 5.7 829 11.5 1,659 18.9 2,445 25.6 2,618 32.0 8,126 16.4
 Dyslipidemia 79 1.9 186 3.4 347 5.5 817 11.3 1,642 18.7 2,410 25.4 2,349 28.8 7,830 15.9
 Coronary heart disease 8 0.2 12 0.2 28 0.5 67 1.0 146 1.7 334 3.6 359 4.5 954 2.0
 Stroke 12 0.3 14 0.3 34 0.5 58 0.8 106 1.2 192 2.1 211 2.6 627 1.3
 Cancer 144 3.7 218 4.3 327 5.5 447 6.6 657 7.9 845 9.3 685 8.8 3,323 7.1

DISCUSSION

The present report describes the study design and profile of participants in the baseline survey of the J-MICC Study, which incorporates 14 study regions from 12 prefectures. We found notable differences in the age distributions of the participants among the study region. There are two possible reasons. First, in the Fukuoka and Saga regions, the participants originally enrolled in the J-MICC Study were in principle limited to adults aged 50 years or older and 40 years or older, respectively. Second, according to the 2010 (the middle year of the baseline survey period) National Census of Japan, there was a 1.6-fold difference in the percentage of the population aged 65 years and older between the lowest (17.4%) and highest (27.0%) in the 12 prefectures including the study regions of the J-MICC Study.

Based on the obtained informed consent, we have already analyzed genomic information from a total of 14,539 participants who were selected to be genotyped from 13 study regions (except for the Iga region). Up to March 2020, we have already published several papers regarding genome-wide association analysis or gene–environmental interaction for health outcomes.1222 Moreover, as a bioresources support system, we provide support for studies using biospecimens and data that were collected at the baseline survey of the J-MICC Study, which was also included in the informed consent. Our support includes providing biological resources and data regarding 92,000 individuals and genotype data for genome-wide association study from approximately 14,000 individuals. Information on support content is provided on the Platform of Supporting Cohort Study and Biospecimen Analysis webpage (http://cohort.umin.jp/english/about/bio-resource.html).

The main strengths of the J-MICC Study are as follows. First, we comprehensively collected data on both living circumstances and genomic information as risk factors of cancer and other lifestyle-related diseases. Such information would be useful to establish personalized or tailor-made lifestyle-related disease prevention methods. Our data might also be useful as a reference tool, because it allows to gain access to data on genotype distributions in a large, healthy Japanese population. Second, the J-MICC Study (started in 2005) was the first Japanese genome-cohort study collecting data from all over Japan, mainly in the western regions. The Japan Public Health Center-based Prospective Study for the Next Generation (JPHC-NEXT), a genome-cohort of over 100,000 people, was launched 6 years later.23 This large-scale, population-based prospective study has been designed to identify risk factors for lifestyle-related diseases, which can in turn contribute to the extension of healthy life expectancy and personalized healthcare. The J-MICC and JPHC-NEXT have conducted a validity study by examining all questionnaires for integrated analysis. Additionally, the Tohoku Medical Megabank Community-Based Cohort Study (TMM CommCohort Study) that began in 2013 was a large scale population-based prospective genome cohort mainly in the east coast of Miyagi and Iwate Prefectures in the Tohoku region to assess the long term impact of the Great East Japan Earthquake and to establish personalized prevention based on the genome, metabolome, and other omics information.24 The JPHC-NEXT, TMM CommCohort Study, Tsuruoka Metabolomics Cohort Study,25 and Yamagata Molecular Epidemiological Cohort Study26 use the same or similar questionnaire established in the J-MICC Study. In the near future, the integration of the J-MICC, JPHC-NEXT, TMM CommCohort Study, and others will finally set up a 300,000-strong cohort research base representing the whole of Japan.

Some potential limitations of the J-MICC Study should also be noted. First, the participation rate was not particularly high (33.5%); hence, our results may have been affected by selection bias. One possible explanation could be that the research sites targeting community inhabitants only mailed invitation letters or distributed leaflets for recruitment. Even in the research sites targeting health checkup examinees, many sites recruited participants only by sending a direct request for survey participation along with the health checkup invitation letter. Second, there were differences between research sites in terms of the recruitment methods (eg, mailing invitation letters or distributing leaflets to the general populations). Also, in some of the research sites, the participants received incentives, such as a small honorarium, which can link to selection bias. These differences, in turn, might be the reason why the region-specific participation rate ranged from 19.7% to 69.8%. Third, it is possible that health check-up attendees are more health conscious, suggesting a healthy volunteer effect in this cohort. For example, current smoking rates among this cohort (male 29.8%, female 7.2%) were slightly lower than those in the 2010 National Health and Nutrition Survey (NHNS) in Japan (male 32.2%, female 8.4%). Furthermore, with respect to history of disease, the rates of diabetes and hypertension among this cohort (diabetes: male 9.7%, female 3.6%; hypertension: male 25.6%, female 16.4%) were also lower compared to those in the 2010 NHNS in Japan (diabetes: male 16.6%, female 9.2%; hypertension: male 57.6%, female 42.2%). Thus, any generalizability of the study findings should be considered with caution. Fourth, our study did not include people over 70 years old. Our study population was 35–69 years of age, and at the beginning of the study, this age group had a greater weight of cancer incidence. Caution should be exercised while extending our findings to the general adult population, including the older adults. Lastly, the incidence rate of early-onset cancers in data from the Aichi Cancer Center will likely be higher than that in other study regions because first-visit patients were recruited at this cancer hospital. The Kanagawa region started the baseline survey about 10 years later than the region where the survey was first launched, so the impact of historical background of this region on the participant characteristics may be different. Thus, there was a problem in simply combining the data from all study regions in the analyses; hence, stratified and sensitivity analyses should be performed in future analyses.

In conclusion, in the J-MICC Study, lifestyle and clinical data and biospecimens were collected from more than 90,000 participants. The present report indicated the study design and identified the baseline characteristics of participants of the J-MICC study. This cohort is expected to be a valuable resource for the national and international scientific community in providing evidence supporting longer healthy lives.

ACKNOWLEDGMENTS

The authors are grateful to all the participants of the baseline survey of the J-MICC Study and the staff at each site for their cooperation. This study was funded by Grants-in-Aid for Scientific Research on Priority Areas of Cancer (No. 17015018) and on Innovative Areas (No. 221S0001), and that for Platform of Supporting Cohort Study and Biospecimen Analysis (CoBiA; JSPS KAKENHI Grant Number JP16H06277) from the Japanese Ministry of Education, Culture, Sports, Science and Technology. This study was supported in part by funding for the BioBank Japan Project from the Japan Agency for Medical Research and Development since April 2015, and the Ministry of Education, Culture, Sports, Science and Technology from April 2003 to March 2015.

Conflicts of interest: None declared.

REFERENCES

  • 1.Tamakoshi A, Yoshimura T, Inaba Y, et al. ; JACC Study Group . Profile of the JACC study. J Epidemiol. 2005;15(Suppl 1):S4–S8. 10.2188/jea.15.S4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Watanabe S, Tsugane S, Sobue T, Konishi M, Baba S. Study design and organization of the JPHC Study. J Epidemiol. 2001;11(6 Suppl):S3–S7. 10.2188/jea.11.6sup_3 [DOI] [PubMed] [Google Scholar]
  • 3.Ministry of Health Labour and Welfare. Summary Report of Vital Statistics, 2018. https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai18/dl/kekka30-19626.pdf. Published 2019. Accessed February 7, 2020.
  • 4.Matsuo K, Hamajima N, Shinoda M, et al. Gene-environment interaction between an aldehyde dehydrogenase-2 (ALDH2) polymorphism and alcohol consumption for the risk of esophageal cancer. Carcinogenesis. 2001;22:913–916. 10.1093/carcin/22.6.913 [DOI] [PubMed] [Google Scholar]
  • 5.Suzuki T, Matsuo K, Sawaki A, et al. Alcohol drinking and one-carbon metabolism-related gene polymorphisms on pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:2742–2747. 10.1158/1055-9965.EPI-08-0470 [DOI] [PubMed] [Google Scholar]
  • 6.Park JY, Matsuo K, Suzuki T, et al. Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese population. Carcinogenesis. 2010;31:660–665. 10.1093/carcin/bgq021 [DOI] [PubMed] [Google Scholar]
  • 7.Higashibata T, Hamajima N, Naito M, et al. ENOS genotype modifies the effect of leisure-time physical activity on serum triglyceride levels in a Japanese population. Lipids Health Dis. 2012;11:150. 10.1186/1476-511X-11-150 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hishida A, Wakai K, Naito M, et al. ; J-MICC Study Group . Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - cross-sectional data from the J-MICC study. Lipids Health Dis. 2014;13:162. 10.1186/1476-511X-13-162 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.White E, Hunt JR, Casso D. Exposure measurement in cohort studies: the challenges of prospective data collection. Epidemiol Rev. 1998;20:43–56. 10.1093/oxfordjournals.epirev.a017971 [DOI] [PubMed] [Google Scholar]
  • 10.Hamajima N; J-MICC Study Group . The Japan Multi-institutional Collaborative Cohort Study (JMICC Study) to detect gene-environment interactions for cancer. Asian Pac J Cancer Prev. 2007;8:317–323. [PubMed] [Google Scholar]
  • 11.Naito M, Eguchi H, Okada R, et al. ; J-MICC Study Group . Controls for monitoring the deterioration of stored blood samples in the Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study). Nagoya J Med Sci. 2008;70:107–115. 10.18999/nagjms.70.3-4.107 [DOI] [PubMed] [Google Scholar]
  • 12.Shimanoe C, Hachiya T, Hara M, et al. A genome-wide association study of coping behaviors suggests FBXO45 is associated with emotional expression. Genes Brain Behav. 2019;18:e12481. 10.1111/gbb.12481 [DOI] [PubMed] [Google Scholar]
  • 13.Nakamura Y, Narita A, Hachiya T, et al. A genome-wide association study in the diabetic patients finds the 13q35.43-35.46 locus associated with estimated glomerular filtration rate: the Japan Multi-Institutional Collaborative Cohort Study. J Clin Diabetes. 2018;2:102. [Google Scholar]
  • 14.Hishida A, Nakatochi M, Akiyama M, et al. ; Japan Multi-Institutional Collaborative Cohort (J-MICC) Study Group . Genome-wide association study of renal function traits: results from the Japan Multi-Institutional Collaborative Cohort Study. Am J Nephrol. 2018;47:304–316. 10.1159/000488946 [DOI] [PubMed] [Google Scholar]
  • 15.Nakatochi M, Kanai M, Nakayama A, et al. Genome-wide meta-analysis identifies multiple novel loci associated with serum uric acid levels in Japanese individuals. Commun Biol. 2019;2:115. 10.1038/s42003-019-0339-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Fujii R, Hishida A, Nakatochi M, et al. Association of genetic risk score and chronic kidney disease in a Japanese population. Nephrology (Carlton). 2019;24:670–673. 10.1111/nep.13479 [DOI] [PubMed] [Google Scholar]
  • 17.Nishiyama T, Nakatochi M, Goto A, et al. Genome-wide association meta-analysis and Mendelian randomization analysis confirm the influence of ALDH2 on sleep durationin the Japanese population. Sleep. 2019;42:zsz046. 10.1093/sleep/zsz046 [DOI] [PubMed] [Google Scholar]
  • 18.Koyama T, Kuriyama N, Ozaki E, et al. Genetic variants of RAMP2 and CLR are associated with stroke. J Atheroscler Thromb. 2017;24:1267–1281. 10.5551/jat.41517 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Nakagawa-Senda H, Hachiya T, Shimizu A, et al. A genome-wide association study in the Japanese population identifies the 12q24 locus for habitual coffee consumption: the J-MICC Study. Sci Rep. 2018;8:1493. 10.1038/s41598-018-19914-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hara M, Hachiya T, Sutoh Y, et al. Genomewide association study of leisure-time exercise behavior in Japanese adults. Med Sci Sports Exerc. 2018;50:2433–2441. 10.1249/MSS.0000000000001712 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Usui Y, Matsuo K, Oze I, et al. Impact of PSCA polymorphisms on the risk of duodenal ulcer. J Epidemiol. 2019. 10.2188/jea.JE20190184 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Iwase M, Matsuo K, Nakatochi M, et al. Differential effect of polymorphisms on body mass index across the life course of Japanese: the Japan Multi-Institutional Collaborative Cohort Study. J Epidemiol. 2020. 10.2188/jea.JE20190296 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Sawada N, Iwasaki M, Yamaji T, et al. The Japan Public Health Center-based Prospective Study for the Next Generation (JPHC-NEXT): study design and participants. J Epidemiol. 2020;30:46–54. 10.2188/jea.JE20180182 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hozawa A, Tanno K, Nakaya N, et al. Study profile of The Tohoku Medical Megabank Community-Based Cohort Study. J Epidemiol. 2020. 10.2188/jea.JE20190271 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Tsuruoka Metabolomics Cohort Study (in Japanese). http://tsuruoka-mirai.net/modules/contents/aisatsu.html. Accessed March 6, 2020.
  • 26.Yamagata University Genomic Cohort Consortium, Narimatsu H. Constructing a contemporary gene-environmental cohort: study design of the Yamagata Molecular Epidemiological Cohort Study. J Hum Genet. 2013;58:54–56. 10.1038/jhg.2012.128 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology are provided here courtesy of Japan Epidemiological Association

RESOURCES